...
机译:后移植后CD34 +?在儿童和青少年成年人中造血干细胞移植后的混合逆变为混合斜切性的干细胞,具有原发性免疫缺陷
Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center;
Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center;
Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center;
Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center;
Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center;
Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center;
Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center;
Hoxworth Blood Center University of Cincinnati;
Bone Marrow Transplantation and Immune Deficiency Cincinnati Children's Hospital Medical Center;
CD34+?selected boost; Mixed chimerism; RIC HSCT; Primary immune deficiencies;
机译:后移植后CD34 +?在儿童和青少年成年人中造血干细胞移植后的混合逆变为混合斜切性的干细胞,具有原发性免疫缺陷
机译:后移植后CD34 +选定的干细胞“提升”作为混合斜切位学的干预后,在儿童和青少年成人中减少强度调理HSCT后的混合逆转
机译:后移植后CD34 +选定的干细胞“提升”作为混合斜切位学的干预后,在儿童和青少年成人中减少强度调理HSCT后的混合逆转
机译:造血干细胞移植跨重大遗传障碍:Megadose CD34细胞和其他否决细胞的耐受性诱导
机译:接受同种异体造血干细胞移植的患者的供体选择:加拿大造血干细胞移植医生的优先事项评估。
机译:在非恶性疾病患者中使用Alemtuzumab氟达拉滨和美法仑降低强度的条件进行造血细胞移植的经验显示出良好的结果并且混合嵌合体的风险取决于基础疾病干细胞来源和Alemtuzumab方案
机译:后移植后CD34 +选定的干细胞“提升”作为混合斜切位学的干预后,在儿童和青少年成人中减少强度调理HSCT后的混合逆转